SEC Form 4 · accession 0001209191-17-057916
Epizyme, Inc. · EPZM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Tai-Ching Ho
Officer — Chief Development Officer
Period of report
Oct 24, 2017
Accepted (ET)
Oct 25, 2017 · 12:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001571498
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Commons Stock, par value $0.0001 | Oct 24, 2017 | M | 15,000 | $8.98 | A | 23,123 | D | |
| Common Stock, par value $0.0001F1,F2 | Oct 24, 2017 | S | 15,000 | $16.4394 | D | 8,123 | D | |
| Common Stock, par value $0.0001F3 | holding | — | — | — | 1,000 | I | By Trust | |
| Common Stock, par value $0.0001F3 | holding | — | — | — | 1,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $8.98 | Oct 24, 2017 | M | 15,000 | D | — | Feb 7, 2026 | Common Stock | 15,000 | 5,500 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.30 per share to $16.60 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2These shares are held in a brokerage account jointly owned by the reporting person and his spouse.
- F3These shares are held in trust for the benefit of the reporting person's child. The reporting person's spouse is a trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F4The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F5This option is fully vested.